AngioDynamics Expands European Indications For NanoKnife System To Include Soft Tissue Ablation For Tumors Of Liver, Pancreas, Kidney, And Prostate

Growing Clinical Evidence and Physician Adoption Broaden NanoKnife IRE Technology as Treatment Option for Major Solid Tumor Types

AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer.

The expanded indications increase physician access to the NanoKnife System's irreversible electroporation (IRE) technology across key oncologic applications, supporting the treatment of patients with tumors that may be difficult to resect or located near critical structures.